C-155. Automated Multiplex Assay System for Simultaneous Detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC)
Objective: The VERSANT® CT/GC DNA 1.0
assay,* which can simultaneously detect Chlamydia trachomatis (CT) and Neisseria
gonorrhoeae (GC) in swab and urine specimens, is run on the VERSANT™ kPCR
Molecular System.* Analytical performance characteristics of the assay were
evaluated. Methods: Bacterial DNA was extracted and captured
nonspecifically from panels or patient specimens using silica-based magnetic
particles on the VERSANT Sample Preparation (SP) Module. The purified DNA
target was amplified and detected by kPCR on the Amplification/Detection (AD)
Module. An internal control is incorporated in the assay to monitor the
extraction, target amplification, and detection processes. The assay also
includes a chemical contamination control (UNG). Assay sensitivity was
determined by testing serial dilution panels prepared with heat-inactivated CT
or GC cells in swab (M4RT) and urine. The ability of the assay to detect CT
serovars and GC isolates was evaluated with 15 heat-inactivated CT serovar
panels and 46 GC genomic DNA panels. Analytical assay specificity was evaluated
with over 490 CT/GC-negative urine specimens and 59 different potentially
cross-reactive organisms. A method comparison with Gen-Probe’s APTIMA was
performed using over 470 clinical urine and swab specimens. Results: The
assay yields qualitative results with discrimination of CT and GC targets.
Detection limits for CT and GC targets are 600 and 295 copies/ mL in urine; and
455 and 275 copies/mL in swab. The assay detects a broad range of CT serovars
and GC isolates. The assay demonstrated no false-positive results for both CT
and GC with any of the 59 organisms tested. The specificity of the assay was
99% for the initial test, and 100% for the retest with confirmed negative urine
specimens. The assay demonstrated over 98% agreement with Gen-Probe’s APTIMA
assay. Conclusion: We present a new VERSANT CT/GC DNA 1.0 kPCR assay for
simultaneously detecting CT and GC in swab and urine specimens. Preliminary
analytical performance evaluation has demonstrated that the assay is highly
sensitive and specific, with effective chemical contamination control and
internal control.
* System and assay not yet commercially available.